JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Minerva Neurosciences Inc

Deschisă

4.36 -3.33

Rezumat

Modificarea prețului

24h

Curent

Minim

4.22

Maxim

4.76

Indicatori cheie

By Trading Economics

P/E

Medie Sector

1.717

37.461

EPS

-0.43

Angajați

8

Dividende

By Dow Jones

Următoarele câștiguri

3 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

5.4M

15M

Deschiderea anterioară

7.69

Închiderea anterioară

4.36

Minerva Neurosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 oct. 2025, 15:58 UTC

Principalele dinamici ale pieței

Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial

Comparație

Modificare preț

Minerva Neurosciences Inc Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

$

Despre Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
help-icon Live chat